FAM90A18: A Potential Drug Target and Biomarker for the Treatment of Human Diseases

Target Name: FAM90A18

NCBI ID: G441326

FAM90A18

FAM90A18: A Potential Drug Target and Biomarker for the Treatment of Human Diseases

Abstract:

FAM90A18 (putative protein FAM90A18P/FAM90A19P) is a protein that has been identified as a potential drug target and biomarker for the treatment of various human diseases. Its unique structure and various post-translational modifications (PTMs) make it an attractive target for the development of new therapies. This article will provide an overview of FAM90A18, its putative functions as a drug target and biomarker, and its potential therapeutic applications.

Introduction:

FAM90A18 (putative protein FAM90A18P/FAM90A19P) is a 21-kDa protein that is expressed in various tissues of the human body. It is characterized by a unique N-terminal region that contains a conserved domain known as the FAM90 domain, as well as a C-terminal region that is rich in charged and polar amino acids, including Asp, Glu, and Lys. FAM90A18 has also been identified as a potential drug target and biomarker for the treatment of various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Function:

FAM90A18 is a member of the FAM90 family of proteins, which are characterized by the presence of a conserved N-terminal domain known as the FAM90 domain. This domain is known to play a crucial role in the regulation of various cellular processes, including cell adhesion, migration, and signaling pathways. FAM90A18 also has a C-terminal region that is rich in charged and polar amino acids, including Asp, Glu, and Lys. These features make FAM90A18 an attractive target for the development of new therapies.

FAM90A18 has been shown to play a role in various cellular processes, including cell adhesion, migration, and the regulation of cell signaling pathways. For example, studies have shown that FAM90A18 can interact with various signaling molecules, including TGF-β, FGFR, and PDGF. Additionally, FAM90A18 has been shown to play a role in the regulation of cellular adhesion, as it has been shown to interact with adhesion molecules such as cadherins and integrins.

FAM90A18 has also been shown to be involved in the regulation of various cellular signaling pathways. For example, studies have shown that FAM90A18 can interact with various signaling molecules, including TGF-β, FGFR, and PDGF. Additionally, FAM90A18 has been shown to play a role in the regulation of cellular adhesion, as it has been shown to interact with adhesion molecules such as cadherins and integrins.

Potential Therapeutic Applications:

FAM90A18's unique structure and various post-translational modifications (PTMs) make it an attractive target for the development of new therapies. Its potential therapeutic applications include the treatment of various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the treatment of cancer, FAM90A18 has been shown to have potential as a drug target. Its unique structure and various post-translational modifications make it an attractive target for the development of new therapies for cancer, including breast, lung, and ovarian cancers. Studies have shown that FAM90A18 can interact with various signaling molecules, including TGF-β,

Protein Name: Family With Sequence Similarity 90 Member A18

The "FAM90A18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM90A18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets